Kymera Investor Presentation Deck

KT-333: Desired Translation of PK, PD and Safety As of October 18, 2023 data cutoff (ASH): Disease control in 3 of 5 CTCL patients including 2 PR's and 1 SD; 1 PR in Hodgkin's lymphoma; supports activity in liquid tumors consistent with preclinical data Tumor biopsy, consistent with preclinical findings, demonstrates induction of IFN-y signature with potential to synergize with anti-PD-1 KT-333 generally well tolerated with primarily Grade 1-2 AEs 2 DLTS observed (Gr. 3 stomatitis/arthralgia), both in LGL-L patients at DL5; additional leukemia patients being enrolled at DL3-4 No DLTs in solid tumor/lymphoma patients at any dose level; enrollment continuing at DL5 Next steps: Complete Phase 1a dose escalation in 2024 to inform expansion cohort strategies KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-Class Opportunity to Address STAT3-Driven Pathology Across Diverse Indications First heterobifunctional degrader against an undrugged target in the clinic Clinical development strategy includes monotherapy direct registrational path in STAT3 dependent T cell malignancies Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors to be informed by preclinical data and planned analysis of TME remodeling in solid tumor biopsies from ongoing trial PAGE 32

View entire presentation